XTX Topco Ltd Buys Shares of 231,148 Verrica Pharmaceuticals Inc. (NASDAQ:VRCA)

XTX Topco Ltd purchased a new position in shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 231,148 shares of the company’s stock, valued at approximately $335,000. XTX Topco Ltd owned approximately 0.51% of Verrica Pharmaceuticals as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of VRCA. Quest Partners LLC bought a new position in Verrica Pharmaceuticals in the second quarter valued at about $50,000. Key Financial Inc bought a new stake in shares of Verrica Pharmaceuticals during the 2nd quarter valued at approximately $69,000. Verition Fund Management LLC acquired a new position in Verrica Pharmaceuticals during the 3rd quarter worth approximately $89,000. Jane Street Group LLC lifted its stake in Verrica Pharmaceuticals by 106.5% in the 3rd quarter. Jane Street Group LLC now owns 69,872 shares of the company’s stock valued at $101,000 after purchasing an additional 36,028 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in Verrica Pharmaceuticals by 20.4% in the second quarter. Rhumbline Advisers now owns 26,591 shares of the company’s stock valued at $194,000 after buying an additional 4,514 shares in the last quarter. 42.45% of the stock is currently owned by institutional investors.

Verrica Pharmaceuticals Stock Down 5.6 %

Shares of VRCA opened at $0.72 on Tuesday. The stock’s 50-day moving average price is $1.16 and its two-hundred day moving average price is $3.74. Verrica Pharmaceuticals Inc. has a 12 month low of $0.68 and a 12 month high of $11.41. The company has a market capitalization of $32.74 million, a PE ratio of -0.39 and a beta of 1.40. The company has a current ratio of 1.34, a quick ratio of 1.22 and a debt-to-equity ratio of 29.58.

Verrica Pharmaceuticals (NASDAQ:VRCA) last posted its quarterly earnings data on Monday, November 4th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.12). The company had revenue of ($1.78) million during the quarter, compared to analyst estimates of $7.53 million. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. On average, analysts anticipate that Verrica Pharmaceuticals Inc. will post -1.42 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on VRCA. HC Wainwright downgraded shares of Verrica Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, November 6th. Brookline Capital Management restated a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 2nd. Royal Bank of Canada downgraded Verrica Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their target price for the company from $11.00 to $2.00 in a research report on Tuesday, November 5th. Needham & Company LLC restated a “hold” rating on shares of Verrica Pharmaceuticals in a report on Tuesday, November 5th. Finally, TD Cowen dropped their price objective on shares of Verrica Pharmaceuticals from $15.00 to $10.00 and set a “buy” rating for the company in a report on Monday, October 21st. Four investment analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $9.50.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.